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Chronic inﬂammatory demyelinating polyneuropathy (CIDP) is a condition that mainly affects the pe-
ripheral nervous system; however, the central nervous system has also been involved in rare cases.
Herein, we describe the case of a 33-year-old man with CIDP who presented with progressively blurred
vision and pain with eye movement in both eyes for 1 month. Ocular examination revealed reduced
visual acuities of 0.15 (oculus unitas or OU) and unremarkable fundi (OU). Furthermore, bitemporal visual
ﬁeld defects and prolonged visually evoked potentials were evident. Brain magnetic resonance imaging
revealed nothing remarkable along the optic nerve and chiasm. These ﬁndings were compatible with the
diagnosis of bilateral optic neuritis. The patient’s symptoms and visual acuity improved after 5 days of
intravenous (IV) corticosteroid pulse therapy, which was subsequently replaced by oral prednisolone
therapy with a tapering schedule. The patient’s visual acuity returned to 1.0 (OU) 6 months after
treatment. However, bilateral optic neuritis recurred in 7 months while the patient was on oral pred-
nisolone and azathioprine. IV corticosteroid pulse therapy was subsequently reinitiated and the patient’s
visual acuity returned gradually to 1.0 (OU). Bilateral optic neuritis is a rare manifestation of CIDP. It
responded well to IV corticosteroid therapy in our case.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Chronic inﬂammatory demyelinating polyneuropathy (CIDP) is
deﬁned by the presence of symmetric proximal and distal muscle
weaknesses with sensory symptoms and signs in all four extrem-
ities. In addition, it must also satisfy the electrophysiological fea-
tures consistent with peripheral demyelinating neuropathy.1
Although CIDP is a condition affecting mainly the peripheral ner-
vous system, the central nervous system (CNS) has also been
involved in rare cases. Five cases of CIDP-related optic neuropathy
have previously been reported.2e6 Here, we report a case of bilat-
eral optic neuritis related to CIDP.e no conﬂicts of interest.
mology, Changhua Christian
a County 500, Taiwan, ROC.
. Jou).
ciety of Taiwan. Published by Else2. Case report
A 33-year-old man complained of progressive gait disturbance,
dizziness, as well as numbness and weakness in the distal end of all
four limbs. The patient was ﬁrst admitted to the hospital 2 months
after the initial presentation of his symptoms because of deterio-
rating signs such as tongue numbness, slurred speech, and
dysphagia. The patient denied recent illness, travel history, and
family history. Neurological examination revealed reduced deep
tendon reﬂexes in the distal ends of all four extremities. Electro-
physiological study demonstrated prolonged distal latencies,
reduced nerve conduction velocities, and delayed F responses in the
median, ulnar, and tibial nerves bilaterally. Cerebrospinal ﬂuid
(CSF) analysis revealed nothing remarkable except for an elevated
protein level (195.7 mg/dL; normal range 10e40 mg/dL). Brain
magnetic resonance imaging (MRI) was also unrevealing. Subse-
quently, four regimens of intravenous (IV) immunoglobulin therapy
were administered, which improved the patient’s gait function.
Although no maintenance therapy was subsequently initiated, thevier Taiwan LLC. All rights reserved.
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Nevertheless, the patient developed progressively blurred vision
and pain with eye movement in both eyes in the following month.
An ophthalmologist was consulted approximately 1 month after
the onset of his visual symptoms. Upon presentation, the patient’s
best-corrected visual acuities (BCVAs) were 0.15 bilaterally. Pain
elicited with ocular movement was apparent bilaterally. He could
read 7 out of 15 Ishihara color plate with his right eye and 2 out of
15 with his left eye. Pupils were reactive to light bilaterally without
relative afferent pupillary defect. Visual ﬁeld (VF) examination
disclosed a bitemporal VF defect (Fig. 1A), while visual evoked
potential examination demonstrated prolonged p100 latencies
(Fig. 2). Repeat MRI failed to identify any optic nerve lesion or ev-
idence of multiple sclerosis (MS; Fig. 3). These aforementioned
ﬁndings were compatible with the diagnosis of bilateral optic
neuritis. Other laboratory investigations including complete blood
count, immunoglobulin, complement, chronic reactive protein,
rheumatic factor, antinuclear antibody, tumor markers, and various
viral titers were all negative. Finally, serum antiaquaporin-4 anti-
body assay was also unrevealing.
The patient received IV methylprednisolone for the ﬁrst 3 days
(125 mg q6h), which was then tapered to 80 mg q8h on Day 4 and
reduced again to 40 mg q8h on Day 5. Thereafter, the patient was
maintained on oral prednisolone (60 mg q.d.) and tapered off of it
gradually. The patient’s peripheral numbness and visual acuity
improved soon after the corticosteroid therapy. Eventually, the
patient’s BCVAs returned to 1.0 bilaterally with normal color test.
When the steroid was discontinued after 4 months, unsteady gait
and limb numbness recurred. Consequently, prednisolone (25 mgFig. 1. (A) Visual ﬁeld (VF) showed bitemporal visual ﬁeld defect. (B) Vq.o.d.) and azathioprine (25 mg q.d.) were administered for
maintenance.
Unfortunately, blurred vision (oculus unitas or OU) recurred
following 3 months of maintenance therapy. This time, the BCVAs
were 0.3 (OU) but the patient did not complain of weakness or
numbness of the extremities. VF examination showed generalized
depression with paracentral scotoma in both eyes (Fig. 1B).
Consequently, corticosteroid pulse therapy was reinitiated and the
patient’s BCVAs returned gradually to 0.6 (OU) in 3 weeks. In
addition, azathioprine 25 mg q.d. was added to the treatment
regimen in the following month. Prednisolone was slowly tapered
to 15 mg q.d. to prevent recurrence. Nevertheless, CIDP recurred
with unsteady gait and hand weakness bilaterally 10 months later.
This time, there were no visual symptoms and the patient’s BCVAs
were 1.0 (OU). Corticosteroid pulse therapy was administrated for
3 days, followed by plasma exchange. Those symptoms soon
improved after completing the treatment course. The patient is
currently on oral prednisolone (60 mg q.d.) and azathioprine
(50 mg q.d.).
3. Discussion
CIDP typically presents as a progressive or relapsing, symmetric
motor neuropathy with proximal and distal muscle weaknesses
developing over 2 or more months. Deep tendon reﬂexes are often
reduced or absent.7 Traditionally, CIDP has been considered a het-
erogeneous disorder with a broad spectrum of clinical phenotypes.
The European Federation of Neurological Societies/Peripheral
Nerve Society’s (EFNS/PNS) CIDP treatment guideline has deﬁnedF showed bilateral general depression with paracentral scotoma.
Fig. 2. Prolonged latency of pattern visual evoked potentials in both eyes.
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dominantly distal weakness, and CIDP with focal presentation.1
Although CIDP is considered to be an autoimmune disorder of the
peripheral nervous system, in two large series, CNS involvements
were observed in 5% and 8% of the patients, respectively.8,9
Our patient’s symptoms of bilateral and symmetric muscle
weakness, numbness in the extremities, decreased deep tendon
reﬂexes are compatible with the diagnosis of CIDP. The patient’sFig. 3. Magnetic resonance imaging of optic nerve and chiasm. (A) Axial FLAIR image
did not reveal any optic nerve or intraorbital lesion. (B) Coronal T1-weighted image
after gadolinium injection did not show abnormal enhancement or enlargement of
chiasm.nerve conduction velocity (NCV) examination demonstrated pro-
longed distal latency of medial and ulnar nerve bilaterally, which
also satisﬁes the CIDP’s electrodiagnostic criteria from the EFNS/
PNS guideline.1 In addition, elevated protein levels with normal
white cell counts were also demonstrated repeatedly in our pa-
tient’s CSF. This is also in accordance with the guideline. Unfortu-
nately, nerve biopsy was not performed due to the patient’s refusal.
However, the diagnostic utility of nerve biopsy for suspected CIDP
is still controversial.10 Nerve biopsy is used mainly when other
studies fail to establish the diagnosis of CIDP clearly, particularly
when electrophysiological criteria for demyelination are not met.
In our patient, the diagnosis of chiasmal optic neuritis should be
considered due to bilateral temporal VF defect. Chiasmal optic
neuritis is a clinical syndrome consisting of acute visual loss with a
chiasmal VF defect pattern and/or radiographic demonstration of
chiasmal inﬂammation. The incidence of chiasmal optic neuritis is
rare worldwide, and most are associated with inﬂammatory
demyelinating diseases, most commonly, MS. There were three
cases of MS-related chiasmal optic neuritis11 and one idiopathic
chiasmal optic neuritis12 reported in 2012 in Taiwan. In our case,
the MRI did not reveal any evidence of MS, chiasmal lesion, or other
pathology. Furthermore, chiasmal optic neuritis related to CIDP has
never been reported, and our case was the ﬁrst one.
Including our patient, there have only been six patients, totaling
11 eyes, with CIDP-related optic neuropathies reported in litera-
ture.2e6 The clinical features of these patients are summarized in
Table 1. In these six patients, there were four males and two fe-
males. The patient’s age at the time of diagnosis ranged from 18 to
57 years. Of the ﬁve patients who received MRI with contrast, two
demonstrated optic nerve enhancements, whereas the other three
demonstrated nothing remarkable. The initial visual acuity (VA)s
ranged from counting ﬁngers at 10 to 1 cm. Furthermore, 7 of 11
eyes had initial VAs of 0.15 or worse. All patients had ﬁnal VAs
greater than 0.6 except for one, who had ﬁnal VAs of light
perception (OU) only. However, in comparison with other patients,
this patient with poor ﬁnal VAs was diagnosed with CIDP for more
than 2 decades and suffered several recurrences.
Table 1
Clinical features of six patients with CIDP-related optic neuritis.
Age/Sex Eye Disc Ocular
pain
Initial VA Visual ﬁeld VEP MRI Treatment Follow-up
period/Prognosis
Imamura
et al (1994)
Japan2
35/M OU Swelling þ OD 0.01
OS
0.02
Central scotoma WNL Negative Oral prednisolone
60 mg q.o.d.
2 mo//
OU 1.0
Lee et al (1999)
America3
57/F OU WNL e OD 1.0
OS 0.8
Superior arcuate
defect þ paracentral OD
Inferior nasal þ paracentral OS
Delayed
latency
Right optic
nerve enhancement
Steroid pulse therapy 6 mo/OD 0.8
OS 0.6
Tsai et al (2000)
Taiwan4
32/M OU Mild pallor e OD 0.1
OS
counting
ﬁnger (CF)/
10 cm
Central scotoma Delayed
latency
Left optic
nerve enhancement
Steroid pulse therapy 10 mo, recured
once/OU 0.8
Holtkamp
et al (2001)
Germany5
41/
M
OU Disc atrophy e OD 0.6
OS
0.25
N/A N/A N/A Oral azathioprine þ
prednisolone for CIDP
7 mo/
OU
Light perception
Watanabe (2013),
Japan6
18/F OS Mild pallor þ OD 1.0
OS
0.1
N/A WNL Negative Immunoadsorption 1 y
OU 1.0
Our case, (2013)
Taiwan
33/M OU WNL þ OD 0.15
OS
0.15
Bitemporal VF defect Delayed
latency
Negative Steroid pulse therapy 2 y,
Recurred
once/OU 1.0
CIDP¼ chronic inﬂammatory demyelinating polyneuropathy; MRI¼magnetic resonance imaging; N/A¼ not available; OD¼ oculus dexter; OS¼ oculus sinister; OU¼ oculus
unitas; VEP ¼ visual evoked potential; VF ¼ visual ﬁeld; WNL ¼ within normal limits.
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CIDP-related optic neuritis. According to the optic neuritis treat-
ment trial (ONTT), IV methylprednisolone therapy may lower the
recurrence rate of optic neuritis in comparison with oral prednis-
olone (25% vs. 41%). In addition, high-dose IV methylprednisolone
therapy was found to be more effective in improving short-term
VA, particularly, VF and contrast sensitivity recovery.13 By
contrast, some studies suggest that long-term remissions can be
achieved with pulse high-dose corticosteroids in approximately
25e40% of CIDP patients.14 Therefore, the use of IV steroid was
reasonable in our case. Like previous case reports of CIDP-related
optic neuritis, our experience also conﬁrmed IV steroid’s
effectiveness.
CIDP with optic neuritis may potentially be a new category of its
own. Unfortunately, the number of currently documented patients
is insufﬁcient to make such a distinction. Therewere a few common
traits noted among those with CIPD-related optic neuritis. For
example, it was shown that thosewith optic nerve involvement had
a milder CIDP progression. In addition, the patients were mostly
middle-aged Asian males. Furthermore, they tend to respond
favorably to steroid therapy.
Optic neuritis is a rare manifestation of CIDP, which involves
mainly the peripheral nervous system. Clinicians need to recognize
CIDP as a possible cause of optic neuritis and know that cortico-
steroids can hasten the recovery of visual symptoms. Furthermore,
the maintenance therapy should be tapered off carefully to avoid
CIDP and optic neuritis recurrence.
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